Search results
Showing 811 to 825 of 2107 results for technology appraisal
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
Training and development opportunities at NICE
Training and development opportunities at NICE
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
In development Reference number: GID-TA11565 Expected publication date: 18 November 2026
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
In development Reference number: GID-TA11025 Expected publication date: 10 February 2027
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.